Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARABLE: Sacubitril-Valsartan in Asymptomatic Stage A/B HFpEF
NCT04687111Phase 2Unknown
- Start
- Dec 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms). Primary endpoint: Change in Left Atrial Volume Index at 18 months. Status: unknown.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04687111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687111.